WesBanco Bank’s Intellia Therapeutics NTLA Stock Holding History

WesBanco Bank’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Hold	64,000	–	–	0.03%	372
2026 Q1	$820K	Hold	64,000	–	–	0.02%	403
2025 Q4	$575K	Buy	+64,000	New	+$881K	0.02%	458

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

WesBanco Bank's NTLA Position: Q2 2026 in Review

WesBanco Bank held its Intellia Therapeutics (NTLA) position steady in Q2 2026 at 64,000 shares worth $1.08M. The position accounts for 0.03% of the portfolio, ranked #372.

WesBanco Bank first reported a position in NTLA in Q4 2025 and has held it in 3 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

WesBanco Bank held 64,000 shares of Intellia Therapeutics worth $1.08M as of Q2 2026.
WesBanco Bank left its Intellia Therapeutics share count unchanged in Q2 2026.
Intellia Therapeutics made up 0.03% of WesBanco Bank's portfolio in Q2 2026, its #372 holding.
WesBanco Bank first reported a position in Intellia Therapeutics in Q4 2025 and has held it in 3 quarters since.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on WesBanco Bank's 13F filing for Q2 2026, filed 28 Jul 2026.